Bortezomib
P.L. Zinzani
Institute of Hematology and Medical Oncology University of Bologn, Italy
The incidence of non-Hodgkin's lymphoma (NHL) has markedly increased in the US and Western Europe in recent years and presents a considerable clinical challenge. Despite many advances in the treatment of NHL, the challenge to develop treatments for the disease remains. For example, there are few effective treatment options for patients with mantle cell lymphoma (MCL) and, while there are a number of therapies that can induce remission in patients with follicular lymphoma (FL), the disease remains incurable. Recently, preclinical and clinical studies have shown the potential for proteasome inhibition in the treatment of NHL.
[>Read full article in PDF]